Cemiplimab is a human IgG4 PD-1 antibody [44] that, when used as monotherapy for advanced NSCLC with ≥50% PD-L1 expression, confers survival benefits and progression-free survival compared to chemotherapy (NCT03088540) (Table 1) [48,49]. Here, PDCD1 is linked to non-small cell lung carcinoma.